Generation of a Mouse Model of Von Hippel–Lindau Kidney Disease Leading to Renal Cancers by Expression of a Constitutively Active Mutant of HIF1α

Leiping Fu1,4, Gang Wang1,4, Maria M. Shevchuk2,4, David M. Nanus3,4, and Lorraine J. Gudas1,4

Abstract

Renal cancers are highly aggressive and clinically challenging, but a transgenic mouse model to promote pathologic studies and therapeutic advances has yet to be established. Here, we report the generation of a transgenic mouse model of von Hippel–Lindau (VHL) renal cancer termed the TRACK model (transgenic model of cancer of the kidney). TRACK mice specifically express a mutated, constitutively active HIF1α in kidney proximal tubule (PT) cells. Kidney histologies displayed by TRACK mice are highly similar to histologies seen in patients with VHL disease, including areas of distorted tubular structure, cells with clear cytoplasm and increased glycogen and lipid deposition, multiple renal cysts, and early onset of clear cell renal cell carcinoma (ccRCC). Distorted tubules in TRACK mice exhibit higher levels of CA-IX, Glut1, and VEGF than tubules in nontransgenic control mice. Furthermore, these tubules exhibit increased numbers of endothelial cells, increased cell proliferation, and increased expression of the human ccRCC marker CD70 (TNFSF7). Moreover, PT cells in kidney tubules from TRACK mice exhibit increased genomic instability, as monitored by elevated levels of γH2AX. Our findings establish that activated HIF1α in murine kidney PT cells is sufficient to promote cell proliferation, angiogenesis, genomic instability, and other phenotypic alterations characteristic of human VHL kidney disease, establishing the TRACK mouse as a valid preclinical model of human renal cell carcinoma. Cancer Res; 71(21): 6848–56. ©2011 AACR.

Introduction

Von Hippel–Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations of the VHL tumor suppressor gene (1). Patients with VHL disease have a greatly increased risk of developing various types of tumors, including hemangioblastomas, clear cell renal cell carcinomas (ccRCC), and pheochromocytomas (1). The lifetime risk of developing hemangioblastomas, clear cell renal cell carcinomas (ccRCC) and pheochromocytomas (1). The lifetime risk of developing ccRCC in VHL disease patients is more than 70% by the age of 60 years (2). Loss of expression or mutation of the VHL tumor suppressor gene plays an etiologic role in this cancer syndrome (6). The associated, increased expression of 2 transcription factors, the alpha subunits of hypoxia inducible factor 1 (HIF1α) and HIF2α, may be critical for carcinogenesis (3–5).

VHL disease patient kidneys display cystic changes or distortion of the tubular structure adjacent to cells, which can be differentiated from normal renal parenchyma by histologic evaluation (6). In addition to expressing HIF1α, cells in these early lesions overexpress HIF1α target genes, such as Glucose Transporter 1 (Glut-1), VEGF, and carbonic anhydrase IX (CA-IX; ref. 6). The majority of these early abnormalities are of the “clear” cell type, and a small percentage show changes in nuclear morphology, nuclear to cytoplasm ratio, and tubular architecture. Surrounding areas show increased vascularity. Importantly, HIF1α, but not HIF2α activation occurs in the earliest lesions (6), suggesting a role for HIF1α activation in early renal carcinogenesis. However, this hypothesis remains untested, as many genes are aberrantly expressed in the absence of VHL (1).

The HIF1α protein is regulated posttranslationally under normoxic conditions (7) by interaction with and polyubiquitination by an E3 ubiquitin ligase complex containing VHL protein (pVHL; ref. 8). The polyubiquitinated HIF1α is then targeted to the 26S proteasome for degradation (8). The interaction of HIF1α with pVHL is mediated by hydroxylation of 2 proline residues (P402, 564) in the oxygen-dependent degradation domain (9, 10). Under hypoxic conditions, these proline residues are not hydroxylated, HIF1α, therefore, can not be recognized by pVHL and becomes stabilized. Dimerization of the stabilized HIF1α with the constitutively active HIF1β results in binding of the HIF heterodimer complex to hypoxia responsive elements (HRE, consensus sequence: 5'-RCGTG-3'; ref. 11). Under normoxic conditions HIF1α is also hydroxylated at a conserved asparagine residue (N803) by factor inhibiting HIF1α (FIH-1), whose activity is also oxygen-dependent.
dependent (12). The asparaginyl hydroxylation prevents recruitment of p300 and the transcriptional coactivator protein CBP, resulting in attenuated transcription of HIF1α target genes by HIF1α (13). Because the asparaginyl hydroxylation is also oxygen dependent, under hypoxic conditions HIF1α is not inhibited by FIH-1 and can activate transcription. Mutation of these 3 key amino acids should mimic hypoxic conditions by preventing HIF1α from being degraded by pVHL, and by allowing HIF1α to recruit p300 and CBP, resulting in constitutive expression of HIF1α target genes.

Few mouse models that exhibit the pertinent features of human VHL disease in the kidney exist. Recapitulation of human kidney carcinogenesis by inactivation of the human tumor suppressor gene VHL has not been achieved (14–16). We created a triple mutant (P402A, P564A, N803A) human HIF1α construct using the kidney proximal tubule-specific type I γ-glutamyl transpeptidase (GGT) promoter (17, 18) to drive expression of this triple mutant, constitutively active HIF1α in the proximal tubule cells (PTC). Mice expressing this triple mutant, constitutively active HIF1α construct in the kidney exhibit “clear” cells, renal cysts, disorganized PTs, and cystic clear cell carcinoma, consistent with ccRCC.

Materials and Methods

Plasmid construction

Mutated, constitutively active HIF1α cDNA was created by site-directed mutagenesis (Invitrogen) of conserved proline residues (402, 564) and a conserved asparagine (803) into alanine residues. GGT is specifically expressed in the PTs of the kidney starting at about 3 weeks (17, 18). The rat GGT promoter (−1,930 to +246) was amplified by PCR from a plasmid from Dr. Terzi (18). The GGT promoter, mutated HIF1α, and β-globin poly-A were cloned into pBlueScript and named γGT-HIF1α triple mutant (γ-HIF1α-M3).

Generation of transgenic mice

DNA was prepared as a linearized Clal-XbaI fragment (vector sequence removed) and was injected into pronuclei of one-cell embryos (C57BL/6 × C57BL/6) at the WCMC Mouse Genetics Core. Southern Blot analysis was then done (19).

Tissue dissection, processing, and pathologic review

Tissues were fixed, processed, sectioned, and hematoxylin and eosin stained following standard protocols (20). Slides were reviewed blindly by Dr. Shevchuk, an experienced clinical pathologist specializing in kidney cancer, and independently by a veterinary pathologist, Dr. Sébastien Monette, from the Laboratory of Comparative Pathology, WCMC.

Reverse transcriptase PCR

Total RNA was extracted using mini-RNAeasy columns (Qiagen). Reverse transcriptase PCR (RT-PCR) was then done (21).

Immunostaining

Immunohistochemistry and immunofluorescence were done (22). Antibodies: HIF1α (610958, BD-Transduction); CA-IX (sc-25600, Santa Cruz); Glut-1 (ab14683, Abcam); VEGF (sc-507, Santa Cruz); Cd-31 (550274, BD Pharmingen); PCNA (M0879, Dako) and γH2AX (9718S, Cell Signaling); Cd-31 was stained on cryo-preserved, frozen sections. Periodic Acid/ Schiff (PAS) stain was done on paraffin embedded (23) and cryo-preserved sections. Oil red O (ORO) staining was also done (24).

Statistical analysis

Results are expressed as mean ± SEM. Student t test was used to determine the statistical significance of the γH2AX+ and Ki67+ cell number differences between TG+ and TG− mice.

Results

Generation of transgenic mice expressing mutated, constitutively active HIF1α

A high level of HIF1α protein is a prominent feature of ccRCC (8). Furthermore, increased expression of HIF1α and/or HIF2α, which has 48% amino acid homology with HIF1α, is thought to be a key event in ccRCC carcinogenesis (3). To examine the role of HIF1α in ccRCC carcinogenesis, we constructed a GGT-HIF1α triple mutant plasmid (γ-HIF1α-M3, Fig. 1A). After confirmation of activity in cultured normal kidney proximal tubule cells, γ-HIF1α-M3 transgenic mice were generated from the γHIF1α-M3 plasmid. Five of 51 founder mice harbored the integrated target gene (Fig. 1B, founders #8 to #14). Four lines were evaluated by RT-PCR, using a transgene-specific primer pair (primers 1 and 2, Fig. 1A) for kidney, spleen, liver, heart, lung, intestine, skeletal muscle, and testis/ovary mutant HIF1α mRNA. The triple mutant HIF1α was expressed only in the kidneys of transgenic positive (TG+) mice #8, #25, #32, and #43 (Fig. 1C, panel I, #43 as an example). The transgene was not expressed in other organs analyzed (Fig. 1D). The specific expression of HIF1α in kidney proximal tubules (PT) was also confirmed by immunohistochemistry (see below). VHL, endogenous HIF1α, and endogenous HIF2α mRNA levels were not changed in the kidneys of TG+ compared with the kidneys of transgenic negative (TG−) mice (Fig. 1C, panels 2, 3, 4). All 4 TG+ founder lines, γ-HIF1α-M3-8, γ-HIF1α-M3-25, γ-HIF1α-M3-32, and γ-HIF1α-M3-43, developed normally and passed the transgene to offspring following a Mendelian inheritance pattern.

γ-HIF1α-M3-43 TG+ mice exhibit kidney lesions that histologically resemble human VHL disease

Kidney, spleen, liver, heart, lung, intestine, skeletal muscle, and testis/ovary were removed from TG+ and TG− littersmates, aged 6 to 7 months. Areas of distorted tubular structure were identified with clusters of “clear” cells in the outer cortex of TG+ kidneys from all 4 TG+ lines. These “clear” cells have characteristic proximal tubule cell features, like abundant, acidophilic cytoplasm (Fig. 2A; Fig. 2B, TG+). The γ-HIF1α-M3-43 line exhibited the strongest phenotype (Fig. 2A); the other TG+ lines had similar phenotypes, but they possessed fewer PTs containing ‘clear’ cells (see below). The distorted tubule cells showed moderate to marked cellular...
swelling, cytoplasmic vacuolation (Fig. 2A, black arrows), and prominent cell membranes, a feature of human ccRCC (Fig. 2A). We identified 2 types of vacuolation: large round, discrete vacuoles displacing the nucleus (Fig. 2A, solid black arrow), and vacuoles with pale, eosinophilic to clear feathery cytoplasm without displacement of the nucleus (Fig. 2A, dashed black arrow). The morphology of the large round, discrete vacuoles is consistent with lipid accumulation, while the morphology of the feathery cytoplasm is consistent with glycogen accumulation and hydropic degeneration. These “clear” cell clusters were morphologically strikingly similar to early lesions reported to occur in the “normal” kidneys of patients with VHL disease (6). Because the GGT promoter only drives the expression of the transgene in the PTs, we did not expect abnormalities in the renal medulla or papilla and did not observe any morphologic abnormalities in these regions (not shown). Not all PTs contained these “clear” cell clusters; areas of “normal” PTs were present in the cortex, as assessed by histologic morphology (Fig. 2A, yellow arrow). “Clear” cell PTs covered about 30% to 50% of the cortex in the γ-HIF1α-M3-43 transgenic mice (see below). The majority of histologically abnormal PT cells in TG+ mice were large, simple cuboidal epithelial cells (Fig. 2A, black arrows) and were surrounded by tubular basement membrane, suggesting that these cells are still under proper growth control. Variations in the sizes of the nuclei (anisokaryosis) were identified in these “clear” cells. HIF1α protein was overexpressed in “clear” cells of TG+ (Fig. 2C, arrow), but not TG− kidneys (Fig. 2D) by immunohistochemistry.

In ccRCC, the clear cytoplasm is caused by deposition of glycogen, phospholipids, and neutral lipids, particularly cholesterol esters (25). Similarly, the “clear” cells observed in our TG+ mice contained large amounts of cytoplasmic glycogen and lipid, as shown by Periodic Acid/Schiff (PAS; Fig. 2E, arrow; Fig. 2F, TG−) and ORO staining (Fig. 2G, arrow; Fig. 2H, TG−), respectively. In normal PTs, we detected strong
PAS stain only in the basement membrane and the brush border/luminal side of the PT cells, and not in the cytoplasm. In contrast, in PT cells from TG$^+$ mice strong PAS stain was identified in the cytoplasm, consistent with glycogen accumulation. Similarly, we detected ORO staining in the cortex of TG$^+$ (Fig. 2G) but not TG$^-$ mice (Fig. 2H).

The multiple renal cysts observed (26) in VHL disease patients are believed to be precursors of ccRCC (1, 27). We identified cysts composed of a single layer of epithelial cells in 12-month TG$^+$ mice (Fig. 3A). Dilated blood vessels filled with red blood cells were typically found near cysts. The majority of the cysts had clear spaces within, while some cysts contained amorphous, pale, eosinophilic material (Fig. 3A). Although both tubular and glomerular cysts were found in VHL conditional knockout mice (16), we observed tubular cysts, but not glomerular cysts, in the γ-HIF1α-M3-43 TG$^+$ mice.

The PT cells from 7-month γ-HIF1α-M3-43 TG$^+$ mice show simple, cuboidal epithelial cells with a "clear" morphology. The nuclei of some "clear" cells were large and hyperchromatic, with conspicuous nucleoli, suggestive of a neoplastic change (Fig. 3B and C, arrow). In 14- to 20-month TG$^+$ mice, we observed abnormal PTs with multiple layers of epithelial cells (Fig. 3B and D, arrow). The normal proximal tubule structure is completely disrupted by these disorganized "clear" cells. These abnormal, disorganized "clear" cells form intratubular nests, consisting of multiple layers of cells, and are surrounded by cells with spindle-like nuclei, some of which are endothelial cells (see below), and red blood cells. This has also been observed in foci of VHL disease patient kidneys (6). These abnormal tubules display an intratubular proliferation of atypical clear cells, indicating carcinoma in situ. We examined 15 male γ-HIF1α-M3-43 TG$^+$ mice from 3 to 20 months old. Kidneys of all 15 mice show the expected phenotype. The severity of these histologic changes increases with age (Table 1). Twenty-two-month-old TG$^+$ mice had cystic ccRCC (Fig. 3E). VHL kidney disease features such as "clear" cells, renal cysts, hyperchromatic nuclei, disorganized PTs, and cystic ccRCC were not observed in TG$^-$ mice (Fig. 3F).

Figure 2. "Clear" cells in γ-HIF1α-M3-43 mice. Representative images of histologic morphology (A and B), HIF1α immunohistochemistry (C and D), PAS stain (E and F), and ORO stain (G and H) "clear" cells in 6 month γ-HIF1α-M3-43 male TG$^+$ kidneys (A, C, E, and G) and TG$^-$ kidneys (B, D, F, and H). "Clear" cells, TG$^+$ tubule cells (A, solid, dashed arrows). Large round vacuole displacing the nucleus, solid arrow; feathery cytoplasm without nucleus displacement, dashed arrow. "Normal" PTCs in TG$^+$ kidney (yellow arrow). Increased HIF1α protein in TG$^+$ nuclei (C, arrow). Strong PAS (E, arrow), ORO (G, arrow) staining in cytoplasm of TG$^+$ cells (E and G, arrows). Abnormal PTs with "clear" cells, A, C, E, and G. All PTs stained by PAS or ORO were abnormal PTs with "clear" cells (E and G). Scale bars, 100 μm.

Figure 3. The γ-HIF1α-M3-43 mice show morphologic changes consistent with in situ ccRCC. Representative images of renal cysts (A), a "clear" cell with enlarged nuclei and conspicuous nucleoli (B and C), disorganized PTs (B and D), and cystic ccRCC (E) in γ-HIF1α-M3-43 mice. A, two adjacent renal tubular cysts, 1 filled with amorphous, pale, eosinophilic material, 1 empty. These structures are not observed in TG$^-$ mice (Fig. 2B and 3F). B, low magnification of cortex showing a "clear" cell with enlarged nuclei and one conspicuous nucleolus (C, high magnification) and several TG$^+$ PTs with disorganized, multilayer "clear" cells (D, high magnification). E, cystic ccRCC. F, TG$^-$ control. Scale bars, 100 μm.
normal, PTs of the same TG
VEGF signals in the abnormal, but not in the morphologically

By Western analysis, the CA-IX protein is elevated
suggest that the brush borders of the abnormal PTCs are
some "clear" cells we detect intense VEGF staining close to

CA-IX protein is highly expressed in ccRCC (31). High CA-IX
protein expression increases in ccRCC carcinogenesis (6) and
CA-IX is the major marker used to diagnose ccRCC. CA-IX
expression in the basal and lateral membranes of the abnormal
PTCs in the γ-HIF1α-M3-43 TG⁺ kidneys, but CA-IX was
not easily identified in the luminal membranes/brush borders
(Fig. 4A, arrow). The staining pattern was membranous and
cup-like. The cup-like Glut-1 and CA-IX staining patterns
suggest that the brush borders of the abnormal PTCs are
aberrant. By Western analysis, the CA-IX protein is elevated
30- to 40-fold in the TG⁺ kidneys relative to TG⁻ littermates
(Fig. 4I). CA-IX is a direct target of HIF1α, and CA-IX mRNA is
highly expressed in the kidneys of TG⁺ relative to TG⁻ littermates (Fig. 4J) but not in other tissues in TG⁺ mice
(not shown). We also detected a much higher CD70 mRNA
level in kidneys of TG⁺ versus TG⁻ mice (Fig. 4J). CD70
(TNFSF7) is a marker of human ccRCC (34).

We detected increased Glut-1 in the basal and lateral
membranes of the "clear" cells of abnormal PTCs (Fig. 4C), but
not in blood vessels surrounding the PTs (Fig. 4B).

CA-IX protein expression increases in ccRCC carcinogenesis (6) and
CA-IX protein is highly expressed in ccRCC (31). High CA-IX
protein expression is a diagnostic and prognostic marker for
human ccRCC (32, 33). We detected greatly increased CA-IX
expression in the basal and lateral membranes of the abnormal
PTCs in the γ-HIF1α-M3-43 TG⁺ kidneys, but CA-IX was
not easily identified in the luminal membranes/brush borders
(Fig. 4A, arrow). The staining pattern was membranous and
cup-like. The cup-like Glut-1 and CA-IX staining patterns
suggest that the brush borders of the abnormal PTCs are
aberrant. By Western analysis, the CA-IX protein is elevated
30- to 40-fold in the TG⁺ kidneys relative to TG⁻ littermates
(Fig. 4I). CA-IX is a direct target of HIF1α, and CA-IX mRNA is
highly expressed in the kidneys of TG⁺ relative to TG⁻ littermates (Fig. 4J) but not in other tissues in TG⁺ mice
(not shown). We also detected a much higher CD70 mRNA
level in kidneys of TG⁺ versus TG⁻ mice (Fig. 4J). CD70
(TNFSF7) is a marker of human ccRCC (34).

We detected increased Glut-1 in the basal and lateral
membranes of the "clear" cells of abnormal PTCs (Fig. 4C), but
not in the luminal membranes/brush borders in the γ-HIF1α-
M3-43 TG⁺ mice. We also observed a stronger Glut-1 signal in
some membranes surrounding the clear vacuoles (Fig. 4C,
arrow). The "normal" PTs in TG⁺ kidneys, which are similar
in morphology to normal PTs in TG⁻ kidneys, show much
weaker Glut-1 staining (Fig. 4D).

We detected increased VEGF staining, assessed by immu-
nohistochemistry, in the cytoplasm of the "clear" cells in the
abnormal PTCs (Fig. 4E) in the γ-HIF1α-M3-43 TG⁺ mice. In
some "clear" cells we detect intense VEGF staining close to
empty vacuoles (Fig. 4E, arrow). The morphologically "normal"
PT cells in TG⁺ mice exhibit lower VEGF staining, similar to
the normal PTs in TG⁻ mice (Fig. 4F).

γ-HIF1α-M3-43 TG⁺ mice express Ki67 and γH2AX,
molecular markers of carcinogenesis

Proliferating Cell Nuclear Antigen (PCNA) is an essential
domain of DNA polymerase δ (35) and is expressed during
S phase of the cell cycle; Ki67 is a marker for proliferation (36).
We detected increased numbers of PCNA⁺ or Ki67⁺ cells in the
morphologically abnormal PTs of TG⁺ mice (Fig. 5A, arrows),
but not in the "normal" PTs. In TG⁻ mice, we saw few PCNA⁺
(not shown) or Ki67⁺ cells in the PTs (Fig. 5B, TG⁻).

<table>
<thead>
<tr>
<th>Animal ID</th>
<th>Age at sacrifice (mo)</th>
<th>Clear cell PT area (%)</th>
<th>Number of hyperchromatic nuclei/300× field</th>
<th>Renal cysts (/section)</th>
<th>Carcinoma in situ (/section)</th>
</tr>
</thead>
<tbody>
<tr>
<td>43-102</td>
<td>3</td>
<td>40.4</td>
<td>24.4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>43 × 17-2</td>
<td>3</td>
<td>31.6</td>
<td>8.6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>43-143</td>
<td>4</td>
<td>31.6</td>
<td>7.4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>43-9</td>
<td>6</td>
<td>36.4</td>
<td>11.4</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>43-93</td>
<td>7</td>
<td>30.9</td>
<td>16</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>43-12</td>
<td>12</td>
<td>35.0</td>
<td>1.8</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>43-24</td>
<td>13</td>
<td>38.2</td>
<td>4.8</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>43-13</td>
<td>14</td>
<td>43.0</td>
<td>6.6</td>
<td>1</td>
<td>6</td>
</tr>
<tr>
<td>43 Founder</td>
<td>14</td>
<td>44.4</td>
<td>4.4</td>
<td>26</td>
<td>5</td>
</tr>
<tr>
<td>43-72</td>
<td>14</td>
<td>46.1</td>
<td>7.2</td>
<td>1</td>
<td>8</td>
</tr>
<tr>
<td>43-27</td>
<td>18</td>
<td>27.9</td>
<td>1.8</td>
<td>2</td>
<td>7</td>
</tr>
<tr>
<td>43-10</td>
<td>19</td>
<td>39.1</td>
<td>5.6</td>
<td>3</td>
<td>13</td>
</tr>
<tr>
<td>43-21</td>
<td>20</td>
<td>46.5</td>
<td>6</td>
<td>6</td>
<td>17</td>
</tr>
<tr>
<td>43-20</td>
<td>22</td>
<td>45.5</td>
<td>19.8</td>
<td>8</td>
<td>19</td>
</tr>
<tr>
<td>43-22</td>
<td>22</td>
<td>52.4</td>
<td>22.2</td>
<td>5</td>
<td>18</td>
</tr>
</tbody>
</table>

NOTE: Results from 15 TG⁺ and 15 TG⁻ mice. A summary of TG⁺ mice that exhibit clear cell PTCs, hyperchromatic nuclei, renal cysts, or carcinoma in situ. These abnormalities are not seen in male TG⁻ littermates. Results from TG⁻ littermates are not included.
VEGF (G) is only observed in the abnormal PTs of TG+ and H). Increased staining of CD31 (A), CA-IX (C), Glut-1 (E), and a widely used marker for DSBs (39). Using aylated form of H2A histone family, member X (H2AX) is a marker for DSBs (38). Because the DNA mutation rate is difficult to measure, we measured the numbers of DNA double-strand breaks (DSB) in these “clear” cells. The serine(139) phosphorylation (38). Because the DNA mutation rate is difficult to measure, we measured the numbers of DNA double-strand breaks (DSB) in these “clear” cells. The serine(139) phosphorylation (38). Because the DNA mutation rate is difficult to measure, we measured the numbers of DNA double-strand breaks (DSB) in these “clear” cells. The serine(139) phosphorylation

Genomic instability is another universal feature of tumor cells (37). Premalignant and malignant cells accumulate more mutations than normal cells (37). An increased DNA mutation rate/genomic instability may facilitate neoplastic transformation (38). Because the DNA mutation rate is difficult to measure, we measured the numbers of DNA double-strand breaks (DSB) in these “clear” cells. The serine(139) phosphor-ylation form of H2A histone family, member X (γH2AX) is a widely used marker for DSBs (39). Using a γH2AX antibody, we showed that TG+ mice show a greater number of γH2AX+ cells in the kidneys, especially in the regions of “clear” cells (Fig. 5C, arrow) than TG− mice (Fig. 5D). Almost all of the γH2AX+ cells in the TG+ mice were in clusters of “clear” cells in morphologically abnormal PTs (Fig. 5C). We detected 6 Ki67+ cells and 8 γH2AX+ cells in the TG+ mice compared with 1.5 Ki67+ cells and 2 γH2AX+ cells per high-power field in the TG− mice (P < 0.001; Fig. 5E).

Additional TG+ mouse lines show a similar phenotype

We have 4 independently derived HIF1α transgene TG lines, γ-HIF1α-M3-8, γ-HIF1α-M3-25, γ-HIF1α-M3-32, and γ-HIF1α-M3-43. We analyzed the γ-HIF1α-M3-43 line in greatest detail because it expresses the highest level of the HIF1α transgene. The other 3 TG+ lines express a lower level of the HIF1α transgene. The other 3 TG+ lines express a lower level of the HIF1α transgene (Fig. 6). We observe “clear” cell morphologic abnormalities and increased expression of CA-IX, and γH2AX in PT cells in these additional 3 TG+ lines (Fig. 6A, B, C). We detect increased Ki67 in the γ-HIF1α-M3-32 line, the line that expresses the highest level of HIF1α protein (Fig. 6D). We also observe...
renal cysts in older TG+ mice (Fig. 6E). Thus, the phenotype we describe here is the result of mutant, constitutive HIF1α overexpression.

Discussion

The kidneys of γ-HIF1α-M3 transgenic mice exhibit features of human VHL disease

Loss of the VHL gene plays an important role in the development of ccRCC in some VHL disease patients (3). VHL knockout mouse models have been established (14–16) but they do not recapitulate early human ccRCC well. For example, the "clear" cell phenotype has not been reported (14–16). Although some genes (VEGF, CA-IX) upregulated in human ccRCC showed increased expression and renal cysts were observed in old mice (16), other obvious ccRCC characteristics, such as disorganized, "clear" cell proliferation in PTs, were not observed in the kidneys of such mice.

In contrast, all TG+ mice that express the constitutively active HIF1α construct show the characteristic human VHL disease phenotype in kidney, including "clear" cells, abnormal vascularization, and extremely high CA-IX expression. We also observe some molecular abnormalities usually seen in tumor cells, such as increased cell proliferation and DNA DSBs. Furthermore, we observe abnormalities characteristic of ccRCC, such as renal cysts, disorganized "clear" cell PTs, and CD70 overexpression (34). We observed no abnormalities in other organs of the γ-HIF1α-M3 TG+ mice, most likely because the GGT promoter drives transgene expression only in kidney PT cells, thought to be the cells of origin of human ccRCC (40). We observed that only a subgroup of all PTs exhibited "clear" cells; this may occur because the truncated GGT promoter drives expression in certain segments of PTs. For example, a previously reported, truncated GGT promoter drives expression primarily in the S3 segment of PTs (41).

HIF1α activation is responsible for the phenotype of VHL disease in the kidney

This characteristic human ccRCC phenotype is most likely the result of the increased expression of well-known HIF1α target genes such as Glut-1, VEGF, and CA-IX (42, 43). The upregulation of these genes is only seen in HIF1α expressing, "clear" cell PTs, indicating that these changes are directly related to HIF1α overexpression in these "clear" cell PTs. Increased transcription of HIF1α and Glut-1 changes the metabolism and glucose uptake in HIF1α expressing kidney PTs (11), which may account for the large increase in the accumulation of glycogen and lipids in the cytoplasm of PTs in TG+ mice. Uproregulation of VEGF induces the proliferation of endothelial cells (44), which then likely generates the enhanced vascularization around the abnormal PTs with "clear" cells. CA-IX is upregulated early in carcinogenesis, and CA-IX is now used as the major diagnostic and prognostic marker of human ccRCC (32, 33). Increased expression of CA-IX, observed in TG+ mice and in early VHL disease patients, may play a role in ccRCC carcinogenesis (45).

HIF1α activation can induce genomic instability and cell proliferation

A most interesting observation in the γ-HIF1α-M3 TG+ lines is the induction of DNA DSBs in a small percentage of "clear" cells, as indicated by γH2AX staining (Fig. 5C and E). DNA DSBs can induce genomic instability and carcinogenesis (46). Almost every DNA DSB forms a γH2AX focus, and therefore γH2AX is used to detect DNA DSBs (39). The increased γH2AX staining in some abnormal, "clear" cells indicates increased numbers of DNA DSBs in these TG+ cells. Why overexpression of a mutated, constitutively active HIF1α is associated with increased numbers of DNA DSBs is not known. RAD51, a key mediator of homologous recombination, shows reduced expression under hypoxic conditions (47). In preliminary experiments, we found that RAD51 mRNA was lower in TG+ than in WT kidneys. Whether this is associated with increased numbers of DSBs and/or genomic instability is under investigation.

Increased numbers of PCNA or Ki67+ cells indicate that mutated, constitutively active HIF1α is driving some cells to reenter the cell cycle and proliferate. This is very similar to what has been observed in early kidney lesions of VHL disease patients (6). In these patients, 1% to 2% of the cells in the HIF1α-activated early lesions show Ki67 expression, which is about 4- to 8-fold higher than normal cells.

HIF1α activation can induce VHL disease in the kidney

Renal cysts are observed in more than 60% of VHL disease patients and are thought to be precursors of ccRCC (1). The "clear" cells in the disorganized PTs of TG+ mice (Fig. 3D) are between the stages of carcinoma in situ and frank carcinoma. However, we did not detect late stage ccRCC with invasion and metastasis in TG+ mice. CD70 protein is upregulated in the majority of human ccRCC and is a marker of early human ccRCC (34). CD70 mRNA was higher in older TG+ mice relative to TG- controls (Fig. 4I). This result suggests that there may be some neoplastically transformed,
"clear" cells present. Cigarette smoking, obesity, and hypertension are 3 well-established risk factors for ccRCC (48). We are testing these TG+ mice to determine whether exposure to these conditions results in more rapid neoplastic transformation of PT cells in our TG+ mice.

Our results suggest that activated HIF1α functions as an oncogene in clear cell renal carcinogenesis. Although increased HIF1α protein expression is an early event in many solid tumors (4, 30), HIF1α has only been implicated as an etiologic factor of ccRCC (3). The role of HIF1α in VHL disease, especially in ccRCC carcinogenesis, is of interest because HIF1α is directly regulated by pVHL, which is usually lost or silenced in ccRCC (3). In an earlier publication, when pVHL expression was restored in VHL−/− human ccRCC cells tumorigenesis in a xenograft tumor model was blocked, and stabilization of HIF1α alone did not reproduce the tumor phenotype in these ccRCC cells expressing ectopic pVHL (49). However, HIF1α is not fully activated in this model (49) because hydroxylation of the asparagine (N803) can still occur. Moreover, fully tumorigenic ccRCC cells were used in a xenograft model so the carcinogenesis process was not analyzed (49). In contrast, our TG+ mice allow us to follow the carcinogenesis process over time and assess the early molecular changes that occur.

In summary, our results indicate that this constitutively active HIF1α functions as an oncogene in renal carcinogenesis. Expression of a mutated, constitutively active HIF1α protein in kidney PTs results in a phenotype similar to that observed in patients with VHL disease, including premalignant lesions, multiple renal cysts, and ccRCC.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Acknowledgments**

We thank Dr. Semenza for the HIF1α and Dr. Terzi for the GGT promoter construct.

**Grant Support**

This work was supported by WCMC, the Tuerbisher Kidney Cancer Research Fund, and the Robert H. McCooey Gentourinary Oncology Research Fund. Fu holds the Robert H. McCooey Gentourinary Oncology Research Fellowship. Wang was supported by NCI-R25105012.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received May 25, 2011; revised August 25, 2011; accepted September 6, 2011; published OnlineFirst September 9, 2011.


Generation of a Mouse Model of Von Hippel–Lindau Kidney Disease Leading to Renal Cancers by Expression of a Constitutively Active Mutant of HIF1α

Leiping Fu, Gang Wang, Maria M. Shevchuk, et al.